Showing only trials that are North West England

Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström’s Macroglobulinemia

Understanding the safety and efficacy of a new drug that stops a certain type of protein working

Expected to end: 01/09/2028

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

Studying the long-term effects of Ibrutinib in people who were on previous trials for the drug that have now closed

Expected to end: 29/01/2027

Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström’s Macroglobulinaemia (RAINBOW)

Is ibrutinib and rituximab a more effective first-line treatment than the current standard first-line treatment for people with WM?

Expected to end: 01/03/2030

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Measuring the safety and efficacy of nemtabrutinib, a type of BTK inhibitor

Expected to end: 19/03/2027

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

The first trial in humans for a new type of BTK degrader

Expected to end: 01/01/2028

A study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

An early phase study of the efficacy and safety of a new drug

Expected to end: 08/01/2026

Study to Evaluate CCS1477 in Haematological Malignancies

Finding out more about a new type of targeted treatment

Expected to end: 30/06/2025

Oxford Pre-cancerous Lymphoproliferative Disorders Study (OxPLoreD)

Looking for markers that might predict disease is progressing

Expected to end: 01/10/2025

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Studying long-term data for Venetoclax in people who were previously taking the drug on other trials

Expected to end: 01/02/2026

A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

A first-in-human study to test the safety and efficacy of a new targeted treatment

Expected to end: 31/05/2025